Document:

Exhibit 10.4

 

THE
SECURITIES REPRESENTED HEREBY, INCLUDING THE SHARES ISSUABLE UPON EXERCISE HEREOF, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN
MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL FOR THE
ISSUER, IS AVAILABLE.

 

WARRANT
AGREEMENT

 

No.
1

 

healthlynked
corporation

 

This
Warrant Agreement (this “Agreement”) is dated as of January 1, 2015 (the “Issue Date”)
and entered into by and between HealthLynked Corporation, a corporation organized under the laws of State of Nevada and Dr. Michael
T. Dent, (together with its successors and assigns, the “ Warrant Holder or MTD”).

 

WHEREAS,
the Company and the Warrant Holder entered into three 0% unsecured promissory notes during 2013 & 2014 (the “Promissory
Notes”), pursuant to which, the Warrant Holder and Company agreed to compensate MTD 2,000,000 warrants of common stock
of HealthLynked Corporation to calculate interest on the loans using a 7% interest rate; and

 

WHEREAS,
all of the terms and conditions of such Promissory Notes are incorporated herein by this reference, and all capitalized terms
not separately defined in this Warrant, shall have the same meanings as defined in the Promissory Notes.

 

NOW,
THEREFORE, in consideration of the mutual covenants set forth in this Agreement and for other good and valuable consideration,
the parties agree as follows:

 

1.       Grant
of Warrant. The Company hereby, upon the terms and subject
to the conditions of this Agreement, issues to the Warrant Holder a warrant (the “Warrant”) evidenced by this
Agreement to purchase up to that number of Conversion Securities as shall be equal to 2,000,000 warrants at an exercise price
of $0.05 per share pursuant to the terms hereof, the “Exercise Price”).

 

2.       Term
and Termination of Warrant. The Warrant shall terminate
on the tenth (10th) anniversary of the Issue Date (the “Expiration Date”).

 

3.       Exercise
of the Warrant.

 

(a)      Exercise
and Payment. The purchase rights represented by the Warrant may be exercised by the Warrant Holder, in whole or in part at
any time following the Issue Date during the period prior to the Expiration Date, by the surrender of the Warrant (together with
a duly executed notice of exercise in the form attached hereto as Exhibit A (the "Exercise Notice") at
the principal office of the Company, and by the payment to the Company, at the option of the Warrant Holder by wire transfer of
immediately available funds, of an amount equal to (A) the number of Warrant Shares being purchased upon exercise of the Warrant
multiplied by (B) the Exercise Price (the “Warrant Price”).

 

     

     

    

 

(b)      Warrant
Shares. On or before the first (1st) Business Day (as hereafter defined) following the date on which the Company
has received an Exercise Notice, the Company shall transmit by facsimile an acknowledgment or confirmation of receipt of such
Exercise Notice to the Holder. On or before the third (3rd) Business Day following the date on which the Company has
received such Exercise Notice, so long as the Holder delivers the Aggregate Exercise Price on or prior to the second (2nd)
Business Day following the date on which the Company has received such Exercise Notice, the Company shall issue and deliver to
the Holder or, at the Holder’s instruction pursuant to the Exercise Notice, the Holder’s agent or designee, in each
case, sent by reputable overnight courier to the address as specified in the applicable Exercise Notice, a certificate, registered
in the Company’s shareholder register in the name of the Holder or its designee (as indicated in the applicable Exercise
Notice), representing the number of Warrant Shares to which the Holder is entitled pursuant to such exercise. The Company shall
be responsible for all fees and expenses related to the issuance of such Warrant Shares, if any. Upon delivery of an Exercise
Notice, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant Shares.
If this Warrant is submitted in connection with any exercise pursuant to this Section 3(b) and the number of Warrant Shares represented
by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then, at
the request of the Holder, the Company shall as soon as practicable and in no event later than three (3) Business Days after any
exercise and at its own expense, issue and deliver to the Holder (or its designee) a new Warrant (in accordance with Section 11(d))
representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant,
less the number of Warrant Shares with respect to which this Warrant is exercised. Fractional shares of stock are to be issued
upon the exercise of this Warrant. The Company shall pay any and all taxes and fees which may be payable with respect to the issuance
and delivery of Warrant Shares upon exercise of this Warrant. Following the exercise in full of this Warrant, the Holder shall
deliver this original Warrant certificate to the Company. For purposes of this Warrant, “Business Day” means
any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required
by law to remain closed.

 

(c)      Company’s
Failure to Timely Deliver Securities. If the Company shall fail for any reason or for no reason to issue to the Warrant Holder
within five (5) Business Days of receipt of the Exercise Notice so long as the Warrant Holder delivers the Aggregate Exercise
Price on or prior to the second (2nd) Business Day following the date on which the Company has received the Exercise
Notice, a certificate for the number of Warrant Shares to which the Warrant Holder is entitled and register such Warrant Shares
on the Company’s shareholder register, then, the Warrant Holder is entitled to all remedies available to him Nothing shall
limit the Warrant Holder’s right to pursue any remedies available to it hereunder, at law or in equity, including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver
certificates representing the Warrant Shares (or to electronically deliver such Warrant Shares) upon the exercise of this Warrant
as required pursuant to the terms hereof.

 

    	 	2	 

     

    

 

(d)      Fractional
Warrant Shares. Fractional Warrant Shares will be issued in connection with any exercise hereunder.

 

(e)      Legend.
The Warrant Shares to be acquired by the Holder pursuant hereto, may not be sold or transferred unless (A) such securities
are sold pursuant to an effective registration statement under the Securities Act, or (B) the Company or its transfer agent shall
have been furnished with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of
counsel in comparable transactions and from an attorney who regularly practices securities law) to the effect that the securities
to be sold or transferred may be sold or transferred pursuant to an exemption from such registration or (C) such securities
are sold or transferred pursuant to Rule 144 under the Securities Act (or a successor rule) (“Rule 144”) or
(D) such shares are sold or transferred outside the United States in accordance with Rule 904 of Regulation S under the Securities
Act, or (E) such shares are transferred to an “affiliate” (as defined in Rule 144) of the Company who agrees to sell
or otherwise transfer the shares only in accordance with this Section 3(e). Except as otherwise provided in this Warrant (and
subject to the removal provisions set forth below), until such time as the Warrant Shares issuable upon exercise of the Warrant
have been registered under the Act, otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities
as of a particular date that can then be immediately sold, each certificate for Warrant Shares that has not been so included in
an effective registration statement or that has not been sold pursuant to an effective registration statement or an exemption
that permits removal of the legend, shall bear a legend substantially in the following form, as appropriate:

 

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED. THE HOLDER
HEREOF, BY PURCHASING SUCH SECURITIES, AGREES THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY
(A) TO THE CORPORATION, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES
ACT, (C) WITHIN THE UNITED STATES AFTER REGISTRATION OR IN ACCORDANCE WITH THE EXEMPTION FROM THE REGISTRATION REQUIREMENTS
UNDER THE U.S. SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER, IF APPLICABLE, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS, OR (D) WITHIN THE UNITED STATES IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR
ANY APPLICABLE STATE SECURITIES LAWS AND THE HOLDER HAS PRIOR TO SUCH SALE FURNISHED TO THE CORPORATION AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE CORPORATION.

 

(f)       Removal
of Legend. The legend set forth above shall be removed and the Company shall issue to the Holder a new certificate therefor
free of any transfer legend if (A) the Company shall have received an opinion of counsel, in form, substance and scope customary
for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Securities may be made
without registration under the Act and the shares are so sold or transferred, or (B) (C) in the case of the Conversion Securities
issuable upon exercise of the Warrant, such security is registered for sale by the Holder under an effective registration statement
filed under the Act or otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities as of
a particular date that can then be immediately sold. The Company shall cause its counsel to issue a legal opinion promptly after
the effective date of any registration statement under the Act registering the resale of the Conversion Securities issuable upon
exercise of the Warrant if required to effect the removal of the legend hereunder.

 

    	 	3	 

     

    

 

4.       Securities
Fully Paid; Reservation of Warrant Interests. All of the
Warrant Shares issuable upon the exercise of the Warrant will, upon issuance and receipt of the Warrant Price for such Warrant
Shares, be duly authorized, validly issued, fully paid and non-assessable, and will be free and clear of all taxes, liens, encumbrances
and charges with respect to the issue.

 

5.       Rights
of the Warrant Holder. The Warrant Holder shall have no
voting rights as a member or rights to dividends or other distributions with respect to Warrant Shares subject to this Agreement
until payment in full of the Warrant Price for Warrant Shares being issued and such securities are issued.

 

6.       Adjustment
of Exercise Price and Number of Warrant Shares. The Exercise
Price and the number of Warrant Shares purchasable upon any exercise of the Warrant shall be subject to adjustment from time to
time upon the occurrence of certain events described in this Section 6 if such events occur within the three year period following
the Issue Date.

 

(a)      Subdivision
or Combination of Ownership Shares; Equity Dividend and Interest Conversion.

 

(i)       In
the event the Company should at any time or from time to time fix a record date for the determination of the holders of Ownership
Shares entitled to receive a dividend or other distribution payable in additional Ownership Shares or other securities or rights
directly or indirectly convertible into or exercisable or exchangeable, or rights that entitle the holders of Ownership Shares
to purchase, Ownership Shares (hereinafter referred to as “Ownership Share Equivalents”), without payment of
any consideration by such holders for the additional Ownership Shares or the Ownership Share Equivalents (including the additional
Ownership Shares issuable upon conversion or exercise thereof), then, as of such record date (or the date of such dividend distribution,
split or subdivision if no record date is fixed), (y) the Exercise Price of the Warrant Shares shall be appropriately decreased
or (z) the number of Warrant Shares shall be increased in proportion to such increase of outstanding Ownership Shares and Ownership
Shares issuable with respect to Ownership Share Equivalents.

 

(ii)       If
the number of Ownership Shares outstanding at any time after the Issue Date is decreased by a combination of the outstanding Ownership
Shares, then, upon the record date of such combination, (A) the Exercise Price shall be appropriately increased, or (B) the number
of Warrant Shares shall be decreased in proportion to such decrease in outstanding Ownership Shares.

 

    	 	4	 

     

    

 

(iii)     The Company will not modify its articles of organization or effect any reorganization, recapitalization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities in a manner that negates or avoids the rights of the Warrant Holder to exercise
its rights hereunder, but will at all times assist in the carrying out of all the provisions of this Agreement and in the taking
of all such actions as may be necessary or appropriate in order to protect the Warrant Holder against impairment.

 

(b)      Other
Notices. In the event that the Company shall propose at any time: (i) to declare any dividend or distribution upon any
class or series of securities, whether in cash, property, stock or other securities (including, without limitation, pursuant to
a subdivision of the outstanding shares of capital stock); (ii) to effect any reclassification or recapitalization of its
Ownership Shares outstanding involving a change in such securities; or (iii) to merge or consolidate with or into any other
corporation, or to sell, lease or convey all or substantially all of its property or business, or to liquidate, dissolve or wind
up; then, in connection with each such event, the Company shall mail to the Warrant Holder notice of such transaction:

 

(A)       at
least five (5) business days’ prior written notice in accordance with Section 10 of the date on which a record shall
be taken for such dividend or distribution (and specifying the date on which the holder of the affected class or series of capital
stock shall be entitled thereto) or for determining the rights to vote, if any, in respect of the matters referred to in (c)(ii)
and (c)(iii) above; and

 

(B)       in
the case of the matters referred to in (c)(ii) and (c)(iii) above, written notice of such impending transaction not later than
ten (10) business days’ prior to any shareholders’ meeting called to approve such transaction, or ten (10) business
days’ prior to the closing of such transaction, whichever is earlier, and shall also notify the Warrant Holder in writing
in accordance with Section 10 of the final approval of such transaction by the stockholders of the Company (if such approval
is required). The first of such notices shall describe the terms and conditions of the impending transaction that are material
to a holder of Ownership Shares (as determined by the Board of Directors of the Company (the “Board”) in good
faith) and specify the date on which a holder of Ownership Shares shall be entitled to exchange his, her or its Ownership Shares
for securities or other property deliverable upon the occurrence of such event) and the Company shall thereafter give such holder
prompt notice of any changes in such terms or conditions that are material to a holder of Ownership Shares (as determined by the
Board in good faith). The Company acknowledges that any record date must be set at a date that would permit the Warrant Holder
effectively to exercise its rights hereunder.

 

(c)      Changes
in Ownership Shares. In case at any time prior to the Expiration Date, the Company shall be a party to any transaction (including,
without limitation, a merger, consolidation, sale of all or substantially all of the Company’s assets or recapitalization
of its capital stock) in which the previously outstanding Ownership Shares shall be changed into or exchanged for different securities
of the Company or other securities of another corporation or interests in a non-corporate entity or other property (including
cash) or the Company shall make a distribution on its Ownership Shares, other than regular cash dividends on its outstanding Ownership
Shares, or any combination of any of the foregoing (each such transaction being herein called the “Transaction”
and the date of consummation of the Transaction being herein called the “Consummation Date”), then as a condition
of the consummation of such Transaction, lawful and adequate provisions shall be made so that the Warrant Holder, upon the exercise
hereof at any time on or after the Consummation Date and prior to the Expiration Date, shall be entitled to receive, and this
Agreement shall thereafter represent the right to receive, in lieu of the Warrant Shares issuable upon such exercise prior to
the Consummation Date, the highest amount of securities or other property to which the Warrant Holder would actually have been
entitled as a member upon the consummation of the Transaction if the Warrant Holder had exercised the Warrant immediately prior
thereto. The provisions of this Section 6(c) shall similarly apply to successive Transactions.

 

    	 	5	 

     

    

 

7.       Taxes.
The Warrant Holder acknowledges that upon exercise of the Warrant the Warrant Holder may be deemed to have taxable income in respect
of the Warrant and/or the Warrant Shares. The Warrant Holder acknowledges that any income or other taxes due from it with respect
to the Warrant or the Warrant Interests issuable pursuant to the Warrant shall be the Warrant Holder’s responsibility.

 

8.       Reserved.

 

9.       Representations
and Warranties.

 

(a)      Representations
and Warranties by the Warrant Holder. The representations and warranties of the Warrant Holder set forth in the Promissory
Notes are true and correct in all material respects as of the Issue Date.

 

10.     Non-circumvention.
The Company hereby covenants and agrees that the Company will not, by amendment of its articles of organization or operating agreement,
or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of
securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect
the rights of the Holder.

 

11.     Reissuance
Of Warrants.

 

(a)      Transfer
of Warrant. If this Warrant is to be transferred, the Warrant Holder shall surrender this Warrant to the Company and an opinion
of counsel from an attorney regularly engaged in the practice of securities law, whereupon the Company will forthwith issue and
deliver upon the order of the Warrant Holder a new Warrant (in accordance with Section 11(d)), registered as the Warrant Holder
may request, representing the right to purchase the number of Warrant Shares being transferred by the Warrant Holder and, if less
than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section
11(d)) to the Warrant Holder representing the right to purchase the number of Warrant Shares not being transferred.

 

    	 	6	 

     

    

 

(b)      Lost,
Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification and payment
of any required bond undertaking by the Warrant Holder to the Company in customary form and, in the case of mutilation, upon surrender
and cancellation of this Warrant, the Company shall execute and deliver to the Warrant Holder a new Warrant (in accordance with
Section 11(d)) representing the right to purchase the Warrant Shares then underlying this Warrant.

 

(c)      Exchangeable
for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Warrant Holder at the principal office
of the Company, for a new Warrant or Warrants (in accordance with Section 11(d)) representing in the aggregate the right to purchase
the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such
portion of such Warrant Shares as is designated by the Warrant Holder at the time of such surrender.

 

(d)      Issuance
of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
(i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to
purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 11(a)
or Section 11(c), the Warrant Shares designated by the Warrant Holder which, when added to the number of Conversion Securities
underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying
this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance
Date, and (iv) shall have the same rights and conditions as this Warrant.

 

12.     Amendment
And Waiver. Except as otherwise provided herein, the provisions
of this Warrant may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required
to be performed by it, only if the Company has obtained the written consent of the Warrant Holder.

 

13.     Dispute
Resolution.

 

(a)      This
Warrant shall be governed by, and construed in accordance with, the internal laws of the State of Florida without regard to the
choice of law principles thereof. Each of the parties of the Warrant hereto irrevocably submits to the exclusive jurisdiction
of the courts of the State of Florida located in Dade County and the United States District Court for the Southern District of
Florida in Miami for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Warrant. Service
of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by
the same methods as are specified for the giving of notices under the Subscription Agreement. Each of the parties of this Warrant
irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in
such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought
in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought
in an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT
TO THIS WARRANT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

    	 	7	 

     

    

 

(b)      Each
party shall bear its own expenses in any litigation conducted under this section.

 

(c)      The
Company consents to accept service of process by the certified mail, return receipt requested in the event of litigation. The
Company further consents to accept service of process via recognized international courier in the case that the Company is not
able to accept service by the certified mail provided a receipt of delivery is available. 

 

14.     Remedies,
Other Obligations, Breaches And Injunctive Relief. The remedies
provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the Subscription
Agreement, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein
shall limit the right of the Warrant Holder to pursue actual damages for any failure by the Company to comply with the terms of
this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Warrant
Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any
such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to
an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being
required. The Company shall provide all information and documentation to the Warrant Holder that is requested by the Holder to
enable the Holder to confirm the Company’s compliance with the terms and conditions of this Warrant (including, without
limitation, compliance with Section 6 hereof).

 

15.     Transfer.This
Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company.

 

16.     Severability.
If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect
the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without
material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity
or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations
of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will
endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s),
the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

17.     Assignability.
Notwithstanding anything contained herein to the contrary, subject to the transfer and securities law restrictions set forth in
this Agreement, the Warrant Holder may assign, convey or transfer, in whole or in part, its rights under this Agreement and provide
written notice to Company of any such assignment, conveyance or transfer. Upon any transfer, assignment, pledge, hypothecation
or other disposition of the Warrant or of any rights granted hereunder in accordance with the terms of this Section 17,
the Company shall if necessary issue or re-issue warrant agreements reflecting the appropriate rights and entitlements of the
Warrant Holder and any transferee, assignee or pledgee after giving effect to such transfer, assignment or pledge.

 

18.     Notice.
Any notice to be provided hereunder, unless otherwise herein specified, shall be provided in the manner set forth in the Promissory
Notes.

 

[signatures
on following page]

 

    	 	8	 

     

    

 

IN
WITNESS WHEREOF, the undersigned hereby execute this Agreement as of the day and year first above written.

 

	 	COMPANY:
	 	 	 
	 	HEALTHLYNKED
    CORPORATION
	 	 	 
	 	By:	     
	 	 	Name:
    George O'Leary
	 	 	Title:
    CFO
	 	 	 
	 	WARRANT
    HOLDER:
	 	 	 
	 	By:	 
	 	 	Name:
    Dr. Michael T. Dent
	 	 	Title:
    Chairman

 

 

 

 

 

 

 

 

 

[Signature
Page – Warrant Agreement]

 

     

     

    

 

EXHIBIT
A

 

NOTICE
OF EXERCISE

  

The
undersigned holder hereby exercises the right to purchase _________________ shares of ______________ (“Warrant Shares”)
of HealthLynked Corporation, a Nevada Corporation (the “Company”), evidenced by the attached Warrant No. 1
(the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings
set forth in the Warrant.

  

1.
Form of Exercise Price. The Warrant Holder intends that payment of the Exercise Price shall be made as:

 

____________a
“Cash Exercise” with respect to _________________ Warrant Shares.

  

2.
Payment of Exercise Price. The holder shall pay the Aggregate Exercise Price in the sum of $___________ to the Company in accordance
with the terms of the Warrant.

 

3.
Delivery of Warrant Shares. The Company shall deliver to the holder __________ Warrant Shares in accordance with the terms of
the Warrant.

 

Date:
_______________ __, ______

 

	 	 
	Name
    of Registered Holder	 
	 	 	 
	By:	 	 
	 	Name:
    Dr. Michael T. Dent	 
	 	Title:
    ChairmanExhibit
10.5

 

 

Delaney
Equity Group, LLC

 

FINRA
/ SIPC MEMBER

 

November
2, 2015

 

Dr.
Michael Dent CEO

HealthLynked
Corporation

1726 Medical Blvd. Suite101

Naples,
Florida 34110 United States

Phone:
800-123-1234

Website:
http://www.healthlynked.com

 

Re:
Advisor Consulting, Banking Agreement

 

Dear
Michael,

 

This
Advisor Consulting Agreement (this "Agreement") will confirm that, HealthLynked Corporation engages Delaney
Equity Group, LLC. ("Delaney"), to act alone or with other firms on a best efforts basis as its non-exclusive,
Advisor/Consultant on a commercially reasonable basis using its best efforts to provide certain Services (as defined below) to
the Company in accordance with the terms and conditions set forth herein; Delaney hereby agrees to provide such Services on a
commercially reasonable best effort basis to the Company in accordance with such terms and conditions. Delaney makes no assurances
that the provision of the Services hereunder will be successful. This proposal is valid for seven business days. Now, therefore,
in consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:

 

		1.	For
                                         the purposes of this Agreement, the term "Services" shall include efforts
                                         to Advise the Company and/or any of its Projects, or otherwise arrange for the Company
                                         to receive capital on terms and conditions acceptable to the Company, through any legal
                                         means, whether equity, debt or any combination thereof, (collectively, a "Financing")

 

		2.	For
                                         the purposes of this Agreement, an Accredited Investor, as such term is defined in Rule
                                         501 of Regulation D, shall be considered to have been introduced to the Company by or
                                         through Delaney if the Accredited Investor was first introduced to the Company directly
                                         by Delaney, its agents or employees, (a "Delaney Referred Investor"). Delaney
                                         agrees to designate, in writing, conference call, or by email a Delaney Referred Investor
                                         at the time the referral is made "and Health Lynked Corporation agrees to either
                                         accept or reject such referral promptly within 2 business days."

 

2401
PGA Blvd. Suite 110 Palm Beach Gardens, Florida 33410     Ph: 561-202-6004 Fax: 561-828-0932

 

    	 		 

     

    

 

		3.	Nothing
                                         contained in this Agreement shall be construed as an offer by Delaney or any of its affiliates
                                         to extend credit. In addition, Delaney does not provide legal, tax or accounting services
                                         and does not render such advice.

 

		4.	The
                                         "Term" of this Agreement shall extend from the date of this agreement for a
                                         period of One (1) year and
                                         automatically renew unless Delaney is contacted by the company in writing at least 60
                                         days prior or until delivery of 30 days written notice by the Company to Delaney to terminate
                                         this agreement at any time, with or without cause (the "Termination Date"),
                                         provided, however, that the termination of this Agreement shall not in any way limit,
                                         modify or otherwise affect the rights of Delaney to: (i) receive its entire compensation
                                         pursuant to the terms of this Agreement in connection with any services or a Financing
                                         involving the Company during the Term of this Agreement or subsequent to the termination
                                         or expiration of this Agreement as provided in Section 5(a)(v) below, (ii) receive reimbursement,
                                         on an accountable basis and in an amount not to exceed $500.00, of expenses incurred
                                         by Delaney up to the date of termination or expiration of this Agreement pursuant to
                                         the terms of Section 5(a)(iv) hereof, and (iii) be protected by the indemnification
                                         rights, waivers and other provisions of this Agreement. Delaney will submit the sales
                                         materials, any preliminary/introductory letter or memorandum and all other material written
                                         information to the Company for approval before distributing. The Company will authorize
                                         distribution or provide comments to Delaney within two business days after receiving
                                         such material.

 

		5.	In
                                         consideration of the performance of the Services pursuant to this Agreement, the Company
                                         shall compensate Delaney as follows:

 

Upon
the execution of this Agreement, the Company will pay to Delaney a fee $5,000.00 dollars payable at signing. Said funds will be
used to defray the cost of performing initial due diligence background checks, etc in conformity with the rules of the Financial
Industry Regulatory Authority ("FINRA"), and for a site visit when appropriate. Delaney agrees to share this due diligence
with Delaney referred investors should the information be requested and the distribution of the information meet with Delaney's
customary business practices.

 

	 	a.	The obligation of the Company to pay fees under this
section 5 a. of the agreement shall not arise until upon the closing of a Financing "on terms accepted in writing by the
Company" with a Delaney Referred Investor, the Company shall pay fees to Delaney promptly following the actual transfer
of Consideration (as defined herein) to the Company, its stockholders, affiliates or subsidiaries. These fees shall consist of
the following:

 

	 	i.	A cash fee equal to seven percent (7.0%) of the aggregate
Consideration received by the Company, its stockholders, affiliates or subsidiaries from said investors relative to a Financing
in equity referred to in this Section 5(a) (i); in addition, the Company shall issue to Delaney warrants (the "Financing
Warrants") Delaney with receive ten percent (10%) of the number of Shares Purchased or the total amount raised which
every is greater. The effective price per share will be the same price the investor pays per share. The cash fee shall be payable
to Delaney by the Company at closing. The Company shall cause the financing warrants to be issued to Delaney within thirty days
of closing of a financing.

 

	 	ii.	Non-accountable expense equal one percent (1.0%) of
the aggregate consideration in equity capital.

 

2401
PGA Blvd. Suite 110 Palm Beach Gardens, Florida 33410     Ph: 561-202-6004 Fax: 561-828-0932

 

    	 	2	 

     

    

 

		iii.	The
                                         Financing Warrants shall be exercisable at the option of the holder for a period of five
                                         (5) years from the date of closing of any financing at an exercise price (the "Financing
                                         Warrant Exercise Price"). At 100% of the investor price. The terms of the Financing
                                         Warrants shall be set forth in an agreement (the "Financing Warrant Agreement")
                                         in form and substance reasonably satisfactory to the Company and Delaney for common shares.
                                         The Financing Warrant Agreement shall contain customary terms, including without limitation,
                                         customary cashless exercise and piggy back registration rights etc. The Company shall
                                         cause the Financing Warrants to be issued to Delaney within 30 days after of Closing.

 

		iv.	If
                                         all or part of the Financing for a particular Company, for Acquisitions, and or Projects
                                         is in the form of non-convertible debt or equity, (i.e.) debt financing transaction etc,
                                         then the cash fee shall be six per cent (6.0%) of the gross amount raised up to $10 million,
                                         5% up to $15 million 4% up to $20 million and thereafter. In addition, the Company shall
                                         issue to Delaney warrants (the "Financing Warrants") equal to seven
                                         and on half percent (7.5%) of the gross dollar amount raised. Said warrants will be exercisable
                                         at 100 % of the five day bid price "VWAP" for ordinary/common shares. In the
                                         event another financing group is introduced by Delaney the company total fees will not
                                         exceed the above. Delaney may assign any or all of its rights to affiliates.

 

		v.	As
                                         a Banker/Advisor Delaney will receive one million common shares of restricted stock at
                                         signing and an additional one million common shares of restricted stock at the closing
                                         of a S-1. Effective delivery will be 30 day from signing and or closing of the S-1 and
                                         be accompanied with a signed corporate resolution from the company's board in both cases.
                                         Delaney will also receive three (3%) of the gross amount of any merger, acquisition or
                                         transaction that the firm advise or introduces and only (.05%) a half of one percent
                                         if Delaney only advise and or reviews documents, etc. Delaney will not receive a 3% advisor
                                         fee on top of a referral fee for a financing or a referral fee on top of advisor fee.
                                         Delaney will also advise and/or review the company new business plan, research report,
                                         shareholder list, becoming a fully reporting company in the US (if it applies) up list
                                         and any aspect with management that might develop. As advisor Delaney will receive $1000
                                         a month starting December 1, 2015. In the event Delaney contracts out for an independent
                                         report and only with the company approval, then the company will be responsible for said
                                         cost.

 

		vi.	Subsequent
                                         Transactions Tail. During the Term of this Agreement, and for a period of twenty four
                                         (24) months after the termination, last closing or expiration of this Agreement, if the
                                         Company consummates a Financing with any Delaney Referred Investor or Group then the
                                         Company shall pay to Delaney all fees and expenses provided hereunder.

 

		b.	Fees
                                         and expenses due Delaney hereunder shall be earned and paid out of the funds received
                                         at the closing of any Financing. It is understood that in the event Delaney brings in
                                         another Investment Bank and or advisor to assist in a deal Delaney will be responsible
                                         for any fees not the company.

 

		c.	Delaney
                                         and/or its affiliates may be a Delaney Referred Investor in any Financing. 

 

2401
PGA Blvd. Suite 110 Palm Beach Gardens, Florida 33410     Ph: 561-202-6004 Fax: 561-828-0932

 

    	 	3	 

     

    

 

	 	d.	During
    the Term of this Agreement and subject to the Company's prior written approval which may not be reasonably withheld, Delaney
    reserves the right to have selected dealers ("Selected Dealers") in good standing with the NYSE and/or
    the Financial Industry Regulatory Authority ("FINRA") participate
    in the Financing, specifically for
    the purposes of assisting the Company in finding qualified accredited investors for any Financing. Such Selected Dealers shall
    be compensated as directed by Delaney. Delaney may a assign any and all right to affiliates.

 

Any
communications specifically required hereunder to be in writing, if sent to Delaney, will be sent by overnight courier providing
a receipt of delivery or by certified or registered mail to it at Delaney Equity Group, LLC, 2401 PGA Blvd. Suite 110 Palm Beach
Gardens, Fl. 33410 ATTN: John Calabria Banking Group and if sent to the Company, will be sent by overnight courier providing a
receipt of delivery or by certified or registered mail to Dr. Michael Dent CEO HealthLynked Corporation 1726 Medical Blvd.
Suite101 Naples, Florida 34110 United States Phone: 800-123-1234 www.healthlynked.com

 

If
this letter correctly sets forth the entire understanding between Delaney and the Company with respect to the foregoing, please
so indicate by signing below, at which time this letter shall become a binding contract.

 

	 	Sincerely,
	 	 
	 	Delaney
    Equity Group, LLC.
	 	 
	 	/s/
    John Calabria
	 	John
    Calabria             Banking Group

 

Accepted
and agreed as of the date first above written:

 

	HealthLynked
                                         Corporation
	 
	 	 
	/s/
    Michael Dent	 
	Dr.
    Michael Dent             President, CEO	 

 

2401
PGA Blvd. Suite 110 Palm Beach Gardens, Florida 33410     Ph: 561-202-6004 Fax: 561-828-0932

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]